{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-069533","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2023-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.957758+00:00","generated_at":"2026-06-07T14:21:21.677265+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"FDA grants Fast Track Designation to Candel's CAN-2409 for pancreatic cancer","bullets":["FDA Fast Track Designation for CAN-2409 (adenovirus immunotherapy) plus valacyclovir in pancreatic ductal adenocarcinoma (PDAC) to improve overall survival.","Phase 2 interim data (Nov 2023): 71.4% estimated survival at 24 and 36 months with CAN-2409 + SoC vs 16.7% for SoC alone in borderline resectable PDAC.","Updated overall survival data from interim analysis expected Q2 2024.","CAN-2409 shown to activate immunologic antitumoral response in 'cold' tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-069533","json":"https://secwatch.observer/filing/0000950170-23-069533.json","markdown":"https://secwatch.observer/filing/0000950170-23-069533.md","text":"https://secwatch.observer/filing/0000950170-23-069533.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023069533/0000950170-23-069533-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023069533/cadl-20231212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:21:21.677265+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}